Within the last few years considerable evidence has accumulated which indicates that changes in HMG-CoA reductase are due primarily, if not solely, to changes in enzyme quantity. These include the changes caused by insulin, glucagon, cholesterol, mevalonolactone, cholestyramine, compactin, cyclic mo
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors: oxime ether analogs of pravastatin
✍ Scribed by Noor Turabi; Richard A. DiPietro; Subbarao Mantha; Carl Ciosek; Lois Rich; Jan-I Tu
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 517 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0968-0896
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme‐A reductase (HMGR) is an effective method of lowering plasma low‐density lipoprotein cholesterol levels. Hemi‐calcium (3R,5S,E)‐7‐(4‐(4‐fluorophenyl)‐6‐isopropyl‐2‐(methyl(1‐methyl‐1H‐1,2,4‐triazol‐5‐yl)amino)pyrimidin‐5‐yl)‐3,5‐dihydrox
The apparent octanol-water partition coefficients (Po/w) and aqueous solubilities for four 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors [pravastatin, lovastatin (mevinolin), mevastatin (compactin), and simvastatin (synvinolin)] were compared. Pravastatin is highly hydrophilic